Waldemar Priebe

Prof. Waldemar Priebe


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2020 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
PSPuja Sharma
Puja Sharma
CRCallie Roberts
Callie Roberts
DHDenise Herpai
Denise Herpai
IFIzabela D. Fokt
Izabela D. Fokt
WPWaldemar Priebe
Waldemar Priebe
WDWaldemar Debinski
Waldemar Debinski
Glioblastoma (GBM) is a complex and heterogeneous tumor that warrants a comprehensive therapeutic approach for treatment. Tumor-associated antigens offer an opportunity to selectively target various components of the GBM microenvironment while sparing the normal cells within the central nervous system. In this study, we conjugated a multivalent vector protein, QUAD 3.0, that can target four receptors: EphA3, EphA2, EphB2, and also IL-13RA2, spanning virtually 100% of the GBM microenvironment, to doxorubicin derivatives. The conjugates effectively bound to all four receptors, although to varying degrees, and delivered cytotoxic loads to both established and patient-derived GBM cell lines, with IC50 values in the low nM range. The conjugates were also non-toxic to animals. We anticipate that the QUAD 3.0 Dox conjugates will be further used in preclinical models and possibly clinics in the foreseeable future.